Mohan, Meera http://orcid.org/0000-0002-6913-6526
Janz, Siegfried http://orcid.org/0000-0002-2229-5511
Brazauskas, Ruta
Dwinell, Michael B.
Teng, Bi Qing
Yun, Grant
Dong, Jing http://orcid.org/0000-0001-9856-5963
Pasquini, Marcelo C.
Giralt, Sergio http://orcid.org/0000-0003-1944-5053
Landau, Heather http://orcid.org/0000-0002-3152-1189
Stadtmauer, Edward
Krishnan, Amrita
D’Souza, Anita http://orcid.org/0000-0002-1092-5643
Funding for this research was provided by:
DH | NIHR | Invention for Innovation Programme (K23 HL141445)
William G. Schuett, Jr., Multiple Myeloma Research Endowment, and the Riney Family Multiple Myeloma Research Initiative
Division of Cancer Prevention, National Cancer Institute (R01 CA226279)
Hanis-Stepka-Rettig Endowed Chair in Cancer Research and the Bobbie Nick Voss Charitable Foundation
Article History
Received: 23 February 2023
Revised: 24 April 2023
Accepted: 28 April 2023
First Online: 6 May 2023
Competing interests
: MM reports institutional research funding from GlaxoSmithKline, Takeda Pharmaceutical Company, Ionis Pharmaceuticals, Bristol-Myers Squibb (BMS), Celgene Corporation and Amgen Inc.; Advisory board fees: Sanofi. MBD is a co-founder and has ownership and financial interests in Protein Foundry, LLC and Xlock Biosciences, LLC. MCP has research support from BMS, Kite Pharma, Janssen, and Novartis and consultancy fees from BMS. SG reports research funding from Amgen, Actinium, Celgene, Johnson & Johnson, Miltenyi, Takeda, Omeros and advisory board for Amgen, Actinium, Celgene, Johnson & Johnson, Janssen, JAZZ Pharmaceutical, Takeda, Novartis, Kite, and Spectrum Pharma. HL reports research funding from Takeda, advisory board fees from Takeda, Pfizer, Janssen, Celgene, Genzyme, Caelum, honorarium from Pfizer and Genzyme. ES reports research funding and consultancy fees from BMS. AK reports research funding from Janssen, SAB Sutro, speaker fees from BMS, Glaxo Smith Kline (GSK), and Takeda, consulting fees from BMS, Janssen, Adaptive, Sanofi, Pfizer, Regeneron, Abbvie, and GSK. AD reports institutional research funding from Abbvie, Caelum, Janssen, Novartis, Prothena, Regeneron, Takeda, consulting fees from Janssen and Prothena, advisory board fees from BMS, Janssen, Kedrion, and Prothena. RB, SJ, BQT, GY, and JD have no conflicts to report.